Home / Clinical Guideline Hubs / Chapter 9.9
Section 9 — Neurology Pending expert review v1.0 · July 2026

Chapter 9.9 — Neurodevelopmental Outcome, Surveillance, and Early Intervention

Board-review synthesis · pending expert review

Educational guideline — verify locally. Complements the injury-specific neurology guidelines (Section 9). Cross-references: HIE (9.1), IVH (9.2), PVL (9.4), hearing/ROP (sensory, Section 13/eye-ear), CMV (infectious).

1. Clinical Overview

Clinical Overview

Neonatal intensive care is judged not by survival alone but by the lives its survivors lead. Outcome is probabilistic, not deterministic: risk factors shift the odds but do not decide the child, and follow-up exists to detect and act on impairment while development is still plastic. Gestational age dominates but risks are cumulative and social factors are powerful and modifiable. The commonest adverse outcome is not cerebral palsy but the subtle, late-appearing cognitive/attentional phenotype of prematurity — which is why surveillance must reach school age and why follow-up is treatment, not merely measurement.

2. Key Clinical Points

Key Clinical Points
  • Gestational age is the dominant, continuous predictor (even late-preterm carries some risk); risks are cumulative and interacting (severe IVH, white-matter injury, HIE, chronic lung disease, sepsis/NEC, severe growth failure, treated ROP compound it).
  • Social/environmental factors (socioeconomic disadvantage, parental education, caregiving quality) exert a powerful influence that grows with age — comparable long-term to many biological risks — and, unlike a haemorrhage, are MODIFIABLE (the rationale for early intervention). Never assess biological risk in isolation from social context.
  • Use CORRECTED age for the first ~2 years (chronological age overstates delay). Early scores predict school-age function only moderately — counsel in probabilities and follow the child; a reassuring two-year assessment does not exclude later learning/executive/attentional difficulty.
  • Cerebral palsy = a non-progressive (static) disorder of movement/posture in the developing brain; a WORSENING course is not CP and warrants evaluation for a degenerative/metabolic disorder. Manifestations still evolve as the child grows.
  • CP topography → type: spastic diplegia (legs>arms) = periventricular white-matter injury (preterm); hemiplegia = focal infarct/stroke; dyskinetic (choreoathetoid) = basal ganglia injury (acute profound HIE or kernicterus); ataxic = cerebellar. Associated impairments (cognition, epilepsy, communication, sensory, feeding) are often more disabling than the motor deficit.
  • Recognise CP early: absent fidgety general movements at a few months corrected age (highly predictive), persistent primitive reflexes, hand preference before ~1 year (→ hemiplegia); MRI supports. Early recognition opens the door to intervention while plasticity is greatest.
  • Cognitive/behavioural phenotype of prematurity: a whole-distribution downward shift plus characteristic weaknesses (executive function, processing speed, attention, visual-motor skills, mathematics); increased (predominantly inattentive) ADHD, autism, and anxiety. Often invisible at two years → extend surveillance to school age; language delay always warrants excluding hearing loss.
  • Structured follow-up targets high-risk graduates (very/extremely preterm; significant brain injury; HIE/therapeutic hypothermia; seizures/meningitis; chronic lung disease; major surgery/ECMO; severe hyperbilirubinaemia/treated ROP; congenital infection/genetic diagnosis; severe growth restriction/poor head growth). Includes surveillance (growth incl. head circumference, neurologic status, development with corrected age), sensory screening, and family/parental-mental-health support.
  • Early intervention works through developmental plasticity (greatest early, declining thereafter): developmental therapies (PT/OT, speech-language), parent-focused interventions (among the most effective for cognition/language), sensory correction (amplification/cochlear implant, refractive/ROP treatment), and addressing social disadvantage — follow-up is treatment, not measurement.

3. References to Verify

Back to Clinical Guideline Hubs